Beyond Avoidance: Advanced Therapies for Contact Dermatitis

Overview

Journal J Allergy Clin Immunol Pract

Specialty Allergy & Immunology

Date 2024 May 31

PMID 38821440

Authors

Lu Yin

Benjamin Ungar

Emma Guttman-Yassky

David E Cohen

Theodora K Karagounis

Affiliations

Soon will be listed here.

Abstract

Contact dermatitis (CD) is a common and burdensome condition divided into irritant contact dermatitis and allergic contact dermatitis. Treatment relies on accurate diagnosis and identification of the trigger, because definitive treatment is irritant or allergen avoidance. However, avoidance is not always possible, such as when the patient is reacting to a necessary medical device, when the trigger is integral to the patient's occupation, and when avoidance is practically untenable. In these cases, treatment is particularly challenging, especially because the literature on treatments in this clinical scenario is limited. In addition, CD has a complex pathophysiology that varies according to the trigger type, leading to variable treatment efficacy. This article reviews the current literature on treatments for CD with a focus on treatments when trigger avoidance is not feasible.

References

Sung C, McGowan M, Machler B, Jacob S . Systemic Treatments for Allergic Contact Dermatitis. Dermatitis. 2018; 30(1):46-53. DOI: 10.1097/DER.0000000000000435. View

Han J, Won K, Chang S, Kim J . Tacrolimus 0.1% ointment in the treatment of allergic contact dermatitis: a new approach. Int J Dermatol. 2014; 53(10):e470-1. DOI: 10.1111/ijd.12641. View

Puza C, Atwater A . Positive Patch Test Reaction in a Patient Taking Dupilumab. Dermatitis. 2018; 29(2):89. DOI: 10.1097/DER.0000000000000346. View

Ruge I, Skov L, Zachariae C, Thyssen J . Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones. Contact Dermatitis. 2020; 83(2):137-139. DOI: 10.1111/cod.13545. View

Oosterhaven J, Politiek K, Schuttelaar M . Azathioprine treatment and drug survival in patients with chronic hand eczema - results from daily practice. Contact Dermatitis. 2017; 76(5):304-307. DOI: 10.1111/cod.12691. View

Leonard A, Guttman-Yassky E . The Unique Molecular Signatures of Contact Dermatitis and Implications for Treatment. Clin Rev Allergy Immunol. 2018; 56(1):1-8. DOI: 10.1007/s12016-018-8685-0. View

Saripalli Y, Gadzia J, Belsito D . Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol. 2003; 49(3):477-82. DOI: 10.1067/s0190-9622(03)01826-7. View

Reines I, Kietzmann M, Mischke R, Tschernig T, Luth A, Kleuser B . Topical application of sphingosine-1-phosphate and FTY720 attenuate allergic contact dermatitis reaction through inhibition of dendritic cell migration. J Invest Dermatol. 2009; 129(8):1954-62. DOI: 10.1038/jid.2008.454. View

Jin P, Yang C, Bai J, Dong L, Zhi L . Successfully treatment with Dupilumab for systemic contact dermatitis following hair dye in a patient with dermatomyositis. J Cosmet Dermatol. 2022; 21(11):6468-6469. DOI: 10.1111/jocd.15112. View

10.

Lin C, Cooles F, Isaacs J . Basic Mechanisms of JAK Inhibition. Mediterr J Rheumatol. 2020; 31(Suppl 1):100-104. PMC: 7361186. DOI: 10.31138/mjr.31.1.100. View

11.

Scheinman P, Vocanson M, Thyssen J, Johansen J, Nixon R, Dear K . Contact dermatitis. Nat Rev Dis Primers. 2021; 7(1):38. DOI: 10.1038/s41572-021-00271-4. View

12.

Ding Y, Ma T, Zhang Y, Zhao C, Wang C, Wang Z . Rosmarinic acid ameliorates skin inflammation and pruritus in allergic contact dermatitis by inhibiting mast cell-mediated MRGPRX2/PLCγ1 signaling pathway. Int Immunopharmacol. 2023; 117:110003. DOI: 10.1016/j.intimp.2023.110003. View

13.

Lopez-Castillo D, Descalzo M, Olmos-Alpiste F, Armario Hita J, Fernandez Redondo V, Garcia Gavin J . Chronic hand eczema: clinical characterization, aetiology, concomitant foot eczema and polysensitization. Eur J Dermatol. 2022; 32(1):99-106. DOI: 10.1684/ejd.2022.4234. View

14.

Hendricks A, Yosipovitch G, Shi V . Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat. 2019; 32(1):19-28. DOI: 10.1080/09546634.2019.1689227. View

15.

Cain D, Cidlowski J . Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17(4):233-247. PMC: 9761406. DOI: 10.1038/nri.2017.1. View

16.

Jacob S . Ciclosporin ophthalmic emulsion - a novel therapy for benzyl alcohol-associated eyelid dermatitis. Contact Dermatitis. 2008; 58(3):169-70. DOI: 10.1111/j.1600-0536.2007.01209.x. View

17.

Cumberbatch M, Kimber I . Tumour necrosis factor-alpha is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization. Immunology. 1995; 84(1):31-5. PMC: 1415198. View

18.

Baumer W, Gorr G, Hoppmann J, Ehinger A, Rundfeldt C, Kietzmann M . AWD 12-281, a highly selective phosphodiesterase 4 inhibitor, is effective in the prevention and treatment of inflammatory reactions in a model of allergic dermatitis. J Pharm Pharmacol. 2003; 55(8):1107-14. DOI: 10.1211/0022357021585. View

19.

Shah P, Milam E, Lo Sicco K, Cohen D . Dupilumab for allergic contact dermatitis and implications for patch testing: Irreconcilable differences. J Am Acad Dermatol. 2020; 83(3):e215-e216. DOI: 10.1016/j.jaad.2020.05.036. View

20.

Amrol D, Keitel D, Hagaman D, Murray J . Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol. 2004; 91(6):563-6. DOI: 10.1016/S1081-1206(10)61535-9. View